Patent ID: 8546452

Claim:
An arylamidrazone compound represented by formula (1): wherein: R 1 is selected from the group consisting of an n-butyl group, a tert-butyl group, a 1-ethylpropyl group, and a 2,2-dimethylpropyl group, which may be substituted with a halogen atom, a C 1 -C 8 alkoxy group; a phenyl group which may be substituted; a 5- to 7-membered aromatic heterocyclic group; a C 2 -C 8 alkoxy group which may be substituted; or —NR 4 R 5 , wherein R 4 and R 5 , which are identical or different, each represent a hydrogen atom or a lower alkyl group which may be substituted, or R 4 and R 5 may be joined with the adjacent nitrogen atom to form a nitrogen-containing heterocyclic ring which may be substituted; R 2 and R 3 , which are identical or different, each represent a hydrogen atom, a halogen atom, a halo-lower alkyl group, a lower alkyl group, a lower alkynyl group, a lower alkoxy group, a cyano group, a lower alkanoyl group or a lower alkylsulfonyl group; A represents a benzene ring or a heterocyclic ring; D represents a single bond or methylene; m represents an integer from 1 to 3; and n represents an integer from 1 to 5, with the proviso that where R 1 is an ethoxy group, R 2 is a 2,4-dichloro group, R 3 is a hydrogen atom, A is a benzene ring, and D is methylene; where R 1 is an ethoxy group, R 2 is a 2,4-dichloro group, R 3 is a hydrogen atom, a 2-methyl group, a 4-methyl group, a 4-methoxy group or a 4-ethoxy group, A is a benzene ring, and D is a single bond, where R 1 is a phenyl, R 2 is hydrogen, D is a single bond, A is a benzene ring, and R 3 is a methyl group, and where R 1 is a phenyl group, R 2 is a hydrogen, D is a single bond, A is a benzene ring and R 3 is a hydrogen atom are excluded, or a pharmaceutically acceptable salt thereof.